Moreover, the 36-month beta value for RVMD is 1.45. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RVMD is 141.30M and currently, short sellers hold a 8.84% of that float. On May 10, 2024, RVMD’s average trading volume was 1.49M shares.
RVMD) stock’s latest price update
Revolution Medicines Inc (NASDAQ: RVMD)’s stock price has plunge by -2.24relation to previous closing price of 38.31. Nevertheless, the company has seen a -4.44% plunge in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-05-01 that REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
RVMD’s Market Performance
Revolution Medicines Inc (RVMD) has seen a -4.44% fall in stock performance for the week, with a 2.60% gain in the past month and a 23.27% surge in the past quarter. The volatility ratio for the week is 3.65%, and the volatility levels for the past 30 days are at 4.64% for RVMD. The simple moving average for the last 20 days is 1.05% for RVMD stock, with a simple moving average of 29.41% for the last 200 days.
Analysts’ Opinion of RVMD
Many brokerage firms have already submitted their reports for RVMD stocks, with Needham repeating the rating for RVMD by listing it as a “Buy.” The predicted price for RVMD in the upcoming period, according to Needham is $46 based on the research report published on April 12, 2024 of the current year 2024.
Raymond James, on the other hand, stated in their research note that they expect to see RVMD reach a price target of $48, previously predicting the price at $36. The rating they have provided for RVMD stocks is “Strong Buy” according to the report published on April 10th, 2024.
Piper Sandler gave a rating of “Overweight” to RVMD, setting the target price at $43 in the report published on March 11th of the current year.
RVMD Trading at 11.10% from the 50-Day Moving Average
After a stumble in the market that brought RVMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.86% of loss for the given period.
Volatility was left at 4.64%, however, over the last 30 days, the volatility rate increased by 3.65%, as shares surge +0.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.00% upper at present.
During the last 5 trading sessions, RVMD fell by -4.44%, which changed the moving average for the period of 200-days by +45.44% in comparison to the 20-day moving average, which settled at $37.06. In addition, Revolution Medicines Inc saw 30.58% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RVMD starting from Anders Jack, who sale 10,000 shares at the price of $40.03 back on May 03 ’24. After this action, Anders Jack now owns 101,959 shares of Revolution Medicines Inc, valued at $400,260 using the latest closing price.
GOLDSMITH MARK A, the of Revolution Medicines Inc, sale 10,000 shares at $35.33 during a trade that took place back on Apr 10 ’24, which means that GOLDSMITH MARK A is holding 30,424 shares at $353,346 based on the most recent closing price.
Stock Fundamentals for RVMD
Current profitability levels for the company are sitting at:
- -121.09 for the present operating margin
- -0.48 for the gross margin
The net margin for Revolution Medicines Inc stands at -106.06. The total capital return value is set at -0.3. Equity return is now at value -36.17, with -32.48 for asset returns.
Based on Revolution Medicines Inc (RVMD), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -5.1. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -59.52.
Currently, EBITDA for the company is -477.88 million with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 1354.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.45.
Conclusion
To wrap up, the performance of Revolution Medicines Inc (RVMD) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
